Copyright West LLC. Minimum 15 minutes delayed.

Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 2, 2019-- Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved...
View HTML
Toggle Summary Dicerna™ to Report Second Quarter 2019 Financial Results and Host Conference Call on August 8, 2019
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 1, 2019-- Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its second quarter 2019 financial...
View HTML
Toggle Summary Dicerna Receives Breakthrough Therapy Designation for DCR-PHXC for Treatment of Primary Hyperoxaluria Type 1 (PH1)
—Designation Follows Recently Reported PHYOX™1 Phase 1 Data Showing Positive Clinical Responses to DCR-PHXC— —FDA Recognizes Primary Hyperoxaluria Types 2 and 3 (PH2 and PH3) as Meeting Criteria for a Serious or Life-Threatening Disease or Condition— CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul....
View HTML
Toggle Summary Dicerna™ to Begin Clinical Development of DCR-A1AT for Treatment of Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
— Company Submitted Clinical Trial Application and Plans to Initiate Multicenter Phase 1/2 Trial in Third Quarter of 2019 — — Alpha-1 Antitrypsin Deficiency-Associated Liver Disease Program Broadens Dicerna’s Commitment to Addressing Chronic Liver Diseases— CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul....
View HTML
Toggle Summary Dicerna™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 1, 2019-- Dicerna™ Pharmaceuticals, Inc. (Nasdaq:DRNA) (the “Company” or “Dicerna”), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved the...
View HTML
Toggle Summary Dicerna™ Presents Additional Data from PHYOX™1 Study of DCR-PHXC in Patients with Primary Hyperoxaluria Type 1 (PH1) and Type 2 (PH2)
—Researchers Report Substantial Oxalate Reduction Following Single-Dose Administration of DCR-PHXC in Additional Patients with PH2— —Enrollment Underway in Pivotal PHYOX2 Trial of DCR-PHXC— CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 21, 2019-- Dicerna TM Pharmaceuticals, Inc....
View HTML
Toggle Summary Globally Recognized Nephrologist Joins Dicerna™ to Support Continued Development of DCR-PHXC for the Treatment of Primary Hyperoxaluria
– Prof. Bernd Hoppe , M.D., Appointed Vice President, Global Medical Affairs at Dicerna – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 20, 2019-- Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi)...
View HTML
Toggle Summary Dicerna™ Hires Industry Veterans to Lead Regulatory Affairs and Patient Advocacy
— Steven Kates , Ph.D., Joins Company as Vice President, Regulatory Affairs — — David Caponera Appointed Head of Patient Advocacy and Patient Services — CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 13, 2019-- Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading...
View HTML
Toggle Summary Dicerna™ Appoints Rob Ciappenelli Chief Commercial Officer
— Company Expands Management Team and Bolsters Commercial Capabilities to Support Continued Growth — CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 4, 2019-- Dicerna™ Pharmaceuticals, Inc. (Nasdaq:DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference...
View HTML
Toggle Summary Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 3, 2019-- Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved...
View HTML